1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. IGEA Pharma N.V.
  6. News
  7. Summary
    IGPH   NL0012768675

IGEA PHARMA N.V.

(IGPH)
  Report
Delayed Swiss Exchange  -  11:31 2022-07-05 am EDT
0.0980 CHF   -9.68%
06/26IGEA PHARMA N : Notice to postpone annual general meeting IGEA Pharma N.V.
PU
06/15IGEA PHARMA N : Note of the Board
PU
06/15IGEA PHARMA N.V. : IGEA to get SIX further approval to the 2021 annual report disclosure
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

IGEA Pharma N.V. Reports Earnings Results for First Half 2021

09/30/2021 | 05:56pm EDT

IGEA Pharma N.V. reports earnings results for first half 2021. The Group did not generate revenue during the first six months of 2021 against previous period revenue of USD 46,800. The net loss for the period is USD 291,500 (previous period: USD 547,300), representing a basic and diluted loss per share of USD 0.012 and USD 0.011 respectively (previous period: basic and diluted loss per share of USD 0.022).


© S&P Capital IQ 2021
All news about IGEA PHARMA N.V.
06/26IGEA PHARMA N : Notice to postpone annual general meeting IGEA Pharma N.V.
PU
06/15IGEA PHARMA N : Note of the Board
PU
06/15IGEA PHARMA N.V. : IGEA to get SIX further approval to the 2021 annual report disclosure
EQ
06/08Igea Pharma Secures $6 Million Funds To Complete Cannabidiol Extraction Facility
MT
06/07IGEA PHARMA N.V. : Igea pharma has signed a preliminary agreement with lmh-an industrial h..
EQ
05/02IGEA Pharma Gets Swiss Bourse Approval To Delay FY21 Annual Report Publication
MT
05/02IGEA PHARMA N.V. : IGEA to get SIX approval to delay the 2021 annual report disclosure
EQ
05/01IGEA PHARMA N : to get SIX approval to delay the 2021 annual report disclosure
PU
02/01IGEA PHARMA N : non-executive board members resigned after completion of the first post-co..
PU
2021IGEA PHARMA N : GBC Research report IGEA Pharma N.V.
PU
More news
Financials
Sales 2020 0,08 M - -
Net income 2020 -1,13 M - -
Net Debt 2020 0,03 M - -
P/E ratio 2020 -11,0x
Yield 2020 -
Capitalization 38,0 M 38,0 M -
EV / Sales 2019 14 500x
EV / Sales 2020 194x
Nbr of Employees 2
Free-Float 30,4%
Chart IGEA PHARMA N.V.
Duration : Period :
IGEA Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,11
Average target price
Spread / Average Target -
Managers and Directors
Vicenzo Moccia Chairman-Management Board
Sector and Competitors